Company BerGenBio ASA

Equities

BGBIO

NO0010650013

Biotechnology & Medical Research

Analysts' Consensus

Business Summary

Sales per Business

Sales per region

Managers

Members of the board

Share class

Shareholders

Company contact information

Sector

EPS Revisions

Quarterly earnings - Rate of surprise

Sector Bio Therapeutic Drugs

Market Closed - Oslo Bors Other stock markets 10:45:00 2024-05-21 am EDT			5-day change	1st Jan Change
0.1312 ^NOK	+0.46%		+7.36%	-52.81%

Mar. 20	Bergenbio Announces Initiation of Phase 2A in First Line Non-Small Lung Cancer Patients with A STK11 Mutation	CI
Feb. 14	BerGenBio ASA Reports Earnings Results for the Full Year Ended December 31, 2023	CI

Bergenbio ASA is a Norway-based clinical-stage biopharmaceutical company focused on developing drugs for aggressive diseases including cancer and severe respiratory infections. The Company's business portfolio comprises such development stage products as oral axillary lymphoscintigraphy (AXL) which is a tyrosine kinase target that mediates aggressive disease. Under normal healthy physiological conditions, there is low expression of AXL. However, in aggressive diseases, such as cancer and severe respiratory infections, AXL signaling is upregulated in response to hypoxia, inflammation, cellular stress and drug treatment. The Company's flagship product is BGB324, is a selective, potent and orally bio-available small molecule AXL inhibitor in Phase II clinical trials in cancer indications and COVID-19. BerGenBio is based in Bergen, Norway with a subsidiary in Oxford, UK.

Number of employees: 25

NOK in Million	2022	Weight	2023	Weight	Delta
Innovative Drugs 100.0 %	0	100.0 %	0	100.0 %	-9.00%

NOK in Million	2022	Weight	2023	Weight	Delta
Norway 100.0 %	0	100.0 %	0	100.0 %	-9.00%

Managers	Title	Age	Since
Martin Olin CEO	Chief Executive Officer	55	21-09-07
Rune Skeie DFI	Director of Finance/CFO	51	18-03-04
Cristina Oliva CTO	Chief Tech/Sci/R&D Officer	-	22-04-24
Gayle Mills PRN	Corporate Officer/Principal	69	20-12-31

Members of the board	Title	Age	Since
Sally Bennett BRD	Director/Board Member	52	20-12-08
Sveinung Hole BRD	Director/Board Member	57	10-08-31
Anders Lennart Tullgren CHM	Chairman	63	22-01-05
Debra Stephanie Barker BRD	Director/Board Member	61	19-03-12

	Vote	Quantity	Free-Float	Company-owned shares	Total Float
Stock A	1	2,688,689,214	2,472,694,294 ( 91.97 %)	0	91.97 %

Name	Equities	%	Valuation
Trond Mohn 22.52 %	880,114,786	22.52 %	12 M kr
Investinor AS 5.562 %	217,417,430	5.562 %	3 M kr
MP Pensjon PK 1.460 %	57,069,659	1.460 %	747 042 kr
Magne Roar Sangolt 1.427 %	55,768,426	1.427 %	730 009 kr
Marit Mohn 1.321 %	51,651,648	1.321 %	676 120 kr
Nordnet Livsforsikring AS 1.129 %	44,133,597	1.129 %	577 709 kr
Fjärde AP-fonden 1.001 %	39,113,922	1.001 %	512 001 kr
Jakob Hatteland 0.9025 %	35,275,000	0.9025 %	461 750 kr
Rongevær 0.7770 %	30,369,946	0.7770 %	397 543 kr
Sarsia Venture Management AS 0.7030 %	27,477,391	0.7030 %	359 679 kr

BerGenBio ASA

Møllendalsbakken 9

5867, Bergen

+47 55 96 11 59

http://www.bergenbio.com

Sell

Buy

Mean consensus

UNDERPERFORM

Number of Analysts

Last Close Price

0.1312 NOK

Average target price

0.7667 NOK

Spread / Average Target

+484.35%

Consensus

Estimates Revisions

Company calendar

Healthcare

Pharmaceuticals & Medical Research

Biotechnology & Medical Research

Biotechnology & Medical Research

Bio Therapeutic Drugs

	1st Jan change	Capi.
BERGENBIO ASA	-52.81%	48.06M
VERTEX PHARMACEUTICALS INCORPORATED	+8.63%	114B
REGENERON PHARMACEUTICALS, INC.	+13.17%	107B
BIONTECH SE	-12.76%	22.22B
ARGENX SE	-3.99%	21.28B
BEIGENE, LTD.	-7.19%	17.51B
WUXI APPTEC CO., LTD.	-39.93%	17.17B
NEUROCRINE BIOSCIENCES, INC.	+6.67%	14.14B
SAREPTA THERAPEUTICS, INC.	+33.90%	12.2B
LEGEND BIOTECH CORPORATION	-28.60%	7.83B

Bio Therapeutic Drugs